[Form 4] Predictive Oncology Inc. Insider Trading Activity
Predictive Oncology Inc. director Gregory St. Clair Sr. was granted 64,680 restricted stock units (RSUs) on 09/09/2025. Each RSU converts to one share upon vesting and the grant carries a $0.00 purchase price. The RSUs vest in full on October 31, 2025, subject to continued service through that date. After the grant, the reporting person is shown as beneficially owning 85,882 shares. The Form 4 was signed on behalf of the reporting person by an attorney-in-fact on 09/11/2025.
Il direttore di Predictive Oncology Inc., Gregory St. Clair Sr., ha ricevuto 64.680 unità di azioni vincolate (RSU) il 09/09/2025. Ogni RSU si converte in una singola azione al vesting e l'assegnazione ha un prezzo di acquisto di $0,00. Le RSU maturano integralmente il 31 ottobre 2025, soggetto al continuo servizio fino a tale data. Dopo la concessione, la persona comunicante è indicata come possessore beneficiario di 85.882 azioni. Il Form 4 è stato firmato per conto della persona comunicante da un procuratore in fact il 11/09/2025.
El director de Predictive Oncology Inc., Gregory St. Clair Sr., recibió 64,680 unidades de acciones restringidas (RSU) el 09/09/2025. Cada RSU se convierte en una acción al vesting y la concesión tiene un precio de compra de $0.00. Las RSU se consolidan por completo el 31 de octubre de 2025, sujeto a continuar prestando servicios hasta esa fecha. Después de la concesión, la persona informante aparece como poseedora beneficiaria de 85,882 acciones. El Formulario 4 fue firmado en nombre de la persona informante por un apoderado el 11/09/2025.
Predictive Oncology Inc.의 이사 Gregory St. Clair Sr.은 64,680개의 제한 주식 단위(RSU)를 2025-09-09에 받았습니다. 각 RSU는 vesting 시 주식 1주로 전환되며, 부여 가격은 $0.00입니다. RSU는 2025년 10월 31일에 전부 vesting되며, 그 날짜까지 계속 근무해야 합니다. 부여 후 보고자은 85,882주를 유익하게 소유하는 것으로 표시됩니다. Form 4는 보고자를 대신해 대리인에 의해 2025-09-11에 서명되었습니다.
Le directeur de Predictive Oncology Inc., Gregory St. Clair Sr., a reçu 64 680 unités d'actions restreintes (RSU) le 09/09/2025. Chaque RSU se convertit en une action lors de la vesting et l'octroi a un prix d'exercice de 0,00 $. Les RSU se vestent intégralement le 31 octobre 2025, sous réserve d'un maintien du service jusqu'à cette date. Après l'octroi, la personne déclarée est indiquée comme bénéficiaire de 85 882 actions. Le Formulaire 4 a été signé au nom de la personne déclarée par un mandataire le 11/09/2025.
Der Direktor von Predictive Oncology Inc., Gregory St. Clair Sr., erhielt am 09/09/2025 64.680 Restricted Stock Units (RSUs). Jede RSU wandelt sich bei Vesting in eine Aktie um, und der Gewährung liegt ein Ausübungspreis von $0,00 zugrunde. Die RSUs vesten vollständig am 31. Oktober 2025, vorbehaltlich fortgesetzter Dienstzeit bis zu diesem Datum. Nach der Gewährung wird die meldende Person als wirtschaftlich berechtigter Eigentümer von 85.882 Aktien geführt. Das Formular 4 wurde im Namen der meldenden Person von einem Prokuristen am 11.09.2025 unterzeichnet.
أُعطي مدير Predictive Oncology Inc.، Gregory St. Clair Sr.، 64,680 وحدة أسهم مقيدة (RSUs) في 09/09/2025. تتحول كل RSU إلى سهم واحد عند الاستحقاق وتبلغ قيمة شراء المنحة $0.00. تستحق RSUs بالكامل في 31 أكتوبر 2025، رهناً باستمرار الخدمة حتى ذلك التاريخ. بعد المنحة، يظهر الشخص المُبلغ عنه كمالك مستفيد من 85,882 سهمًا. تم توقيع النموذج 4 نيابة عن الشخص المُبلغ عنه بواسطة وكيل في تاريخ 11/09/2025.
Predictive Oncology Inc. 的董事 Gregory St. Clair Sr. 于 2025-09-09 获得了 64,680 份受限股票单位(RSU)。每份 RSU 在归属时可转换为一股,授予价格为 $0.00。RSU 将在 2025年10月31日全数归属,前提是其在该日期前持续任职。授予后,披露人被列为受益所有权拥有 85,882 股。Form 4 由披露人代理律师于 2025-09-11 签署。
- Director received equity compensation via 64,680 RSUs, creating alignment with shareholders if vested
- Vesting date is specified (October 31, 2025), providing clear timeline for when shares may be issued
- RSU grant may increase potential shares outstanding upon vesting (post‑transaction beneficial ownership reported as 85,882)
Insights
TL;DR Director received a time‑based RSU grant of 64,680 shares vesting October 31, 2025.
The grant is a non‑cash equity award recorded at a $0.00 transaction price on Form 4, indicating issuance of restricted stock units rather than a market purchase. The size of the grant relative to the reported post‑transaction beneficial ownership of 85,882 shares suggests a material incremental equity position for the reporting person. This is a routine compensation/retention action rather than a market transaction and has a clear vesting date tied to continued service.
TL;DR Time‑based RSUs were granted to a director and vest upon continued service on a specified future date.
The disclosure identifies the award as restricted stock units that vest in full on October 31, 2025, conditioned on continued service. The filing was made by one reporting person and executed by an attorney‑in‑fact, consistent with standard insider reporting practices. The Form 4 provides clear record of timing and ownership following the grant, enabling transparency around insider compensation.
Il direttore di Predictive Oncology Inc., Gregory St. Clair Sr., ha ricevuto 64.680 unità di azioni vincolate (RSU) il 09/09/2025. Ogni RSU si converte in una singola azione al vesting e l'assegnazione ha un prezzo di acquisto di $0,00. Le RSU maturano integralmente il 31 ottobre 2025, soggetto al continuo servizio fino a tale data. Dopo la concessione, la persona comunicante è indicata come possessore beneficiario di 85.882 azioni. Il Form 4 è stato firmato per conto della persona comunicante da un procuratore in fact il 11/09/2025.
El director de Predictive Oncology Inc., Gregory St. Clair Sr., recibió 64,680 unidades de acciones restringidas (RSU) el 09/09/2025. Cada RSU se convierte en una acción al vesting y la concesión tiene un precio de compra de $0.00. Las RSU se consolidan por completo el 31 de octubre de 2025, sujeto a continuar prestando servicios hasta esa fecha. Después de la concesión, la persona informante aparece como poseedora beneficiaria de 85,882 acciones. El Formulario 4 fue firmado en nombre de la persona informante por un apoderado el 11/09/2025.
Predictive Oncology Inc.의 이사 Gregory St. Clair Sr.은 64,680개의 제한 주식 단위(RSU)를 2025-09-09에 받았습니다. 각 RSU는 vesting 시 주식 1주로 전환되며, 부여 가격은 $0.00입니다. RSU는 2025년 10월 31일에 전부 vesting되며, 그 날짜까지 계속 근무해야 합니다. 부여 후 보고자은 85,882주를 유익하게 소유하는 것으로 표시됩니다. Form 4는 보고자를 대신해 대리인에 의해 2025-09-11에 서명되었습니다.
Le directeur de Predictive Oncology Inc., Gregory St. Clair Sr., a reçu 64 680 unités d'actions restreintes (RSU) le 09/09/2025. Chaque RSU se convertit en une action lors de la vesting et l'octroi a un prix d'exercice de 0,00 $. Les RSU se vestent intégralement le 31 octobre 2025, sous réserve d'un maintien du service jusqu'à cette date. Après l'octroi, la personne déclarée est indiquée comme bénéficiaire de 85 882 actions. Le Formulaire 4 a été signé au nom de la personne déclarée par un mandataire le 11/09/2025.
Der Direktor von Predictive Oncology Inc., Gregory St. Clair Sr., erhielt am 09/09/2025 64.680 Restricted Stock Units (RSUs). Jede RSU wandelt sich bei Vesting in eine Aktie um, und der Gewährung liegt ein Ausübungspreis von $0,00 zugrunde. Die RSUs vesten vollständig am 31. Oktober 2025, vorbehaltlich fortgesetzter Dienstzeit bis zu diesem Datum. Nach der Gewährung wird die meldende Person als wirtschaftlich berechtigter Eigentümer von 85.882 Aktien geführt. Das Formular 4 wurde im Namen der meldenden Person von einem Prokuristen am 11.09.2025 unterzeichnet.